Conferenza / Incontro

Tackling the challenge of heterogeneity in EVs analysis: Membrane Sensing Peptides as a novel dimension to the field

Marina Cretich - CNR, Institute oh Chemical and Technology "Giulio Natta" (SCITEC-CNR), Milan, Italy
26 febbraio 2024
Orario di inizio 
16:00
Polo Ferrari 1 - Via Sommarive 5, Povo (Trento)
Aula A208
Organizzato da: 
Dipartimento di Biologia Cellulare, Computazionale e Integrata - CIBIO
Destinatari: 
Comunità universitaria
Partecipazione: 
Ingresso libero
Referente: 
Dipartimento di Biologia Cellulare, Computazionale e Integrata - CIBIO
Contatti: 
comunicazione.cibio@unitn.it

Extracellular Vesicles (EVs), crucial mediators of cell-to-cell communication, hold significant diagnostic potential due to their ability to concentrate protein biomarkers in bodily fluids. However, challenges in isolating EVs from complex biological specimens hinder their widespread use. The preferred strategy involves direct analysis, integrating isolation and analysis solutions, with immunoaffinity methods currently dominating the field. Yet, the heterogeneous nature of EVs poses challenges, as proposed markers may not be as universally present as thought, raising concerns about biomarker screening reliability. This issue extends to EV-mimics and analogues, where conventional methods may lack applicability. Addressing these challenges, we report on Membrane Sensing Peptides (MSP) as "universal" affinity ligands for both EVs and analogues, streamlining capture and phenotyping through Single Molecule Array (SiMoA). MSP ligands enable direct analysis of circulating EVs, eliminating the need for prior isolation. Demonstrating clinical translation, MSP technology detects an EV-associated epitope signature in serum and plasma, distinguishing myocardial infarction from stable angina. Additionally, MSP allows analysis of tetraspanin-lacking Red Blood Cell-derived EVs, overcoming limitations associated with traditional antibody-based methods. Overall, our work underlines the value of MSP as complementary tools to antibodies, advancing EV analysis for clinical diagnostics and beyond and marking the first-ever peptide-based application in SiMoA technology

Download